omniture

Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results

2010-09-20 19:28 1102

    HARBIN, China, Sept. 20 /PRNewswire-Asia/ -- Renhuang Pharmaceuticals, Inc. (AMEX: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced it will host a conference call at 9:00 a.m. Eastern Time on Tuesday, September 21, 2010, to discuss financial results for the third quarter of its fiscal year 2010, ended July 31, 2010.

    Joining Mr. Shaoming Li, Renhuang's Chairman and CEO, will be Mr. Guangtao Li, Vice President, and Ms. Xiaoying Lu, Interim Chief Financial Officer ("CFO").

    To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 877-812-1464. International callers should dial +1 706-902-4248. The conference ID number for the call is 98347783.

    If you are unable to participate in the call at this time, a replay will be available on Tuesday, September 21, 2010 at 12:00 noon Eastern Time, through Tuesday, October 5, 2010. To access the replay, dial 800-642-1687. International callers should dial +1 706-645-9291. The conference ID number for the replay is 98347783.

    About Renhuang Pharmaceuticals, Inc.

    Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

    For more information, please contact:

    Company Contact:

     Renhuang Pharmaceuticals, Inc.

     Ms. Portia Tan, IR Contact   

     Phone: +86-451-8260-2162

     Email: ir@renhuang.com

    CCG Investor Relations:

     Mr. Mark Collinson, Partner

     Phone: +1-310-954-1343 (Los Angeles)

     Email: mark.collinson@ccgir.com

     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President

     Phone: +1-646-213-1915 (New York)

     Email: crocker.coulson@ccgir.com

Source: Renhuang Pharmaceuticals, Inc.
Related Stocks:
AMEX:CBP
collection